Kinnaird, one of Nashville's leading attorneys, to sue the New England Compounding Middle. But, specialists say, the now notorious Compounding Center has a nationwide network of unwitting enablers and accomplices: There are the doctors who overprescribe an invasive back-discomfort therapy that, in research, has not proved useful for most of the patients who get it. And there are the patients, surviving in an medicalized society increasingly, who want a quick fix for life's pains and aches . This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health News, an unbiased news service editorially, is an application of the Kaiser Family Foundation, a nonpartisan healthcare policy research organization unaffiliated with Kaiser Permanente.‘The standard of our technology will always be the primary driver for generating fresh collaborations, but our pharma partners are searching for unrestricted long-term access increasingly,’ said Man Van Meter, Adimab’s Senior Director of Business Advancement. ‘Adimab’s platform, unlike many other antibody discovery systems, is clear of target restrictions. In addition, Adimab provides its pharma companions with their own library diversity that’s not the same as what their rivals have. Adimab’s capability to transfer that capacity to them has produced considerable interest in the industry.’ Related StoriesMorphoSys, Immatics partner to develop novel antibody-based therapies against multiple proprietary cancers antigensG7 Therapeutics, MorphoSys collaborate on novel antibody therapeutics targeting ion and GPCRs channelsCMC Biologics, River Vision sign manufacturing contract for Teprotumumab to treat Grave's OrbitopathyAdimab and Biogen Idec , of Weston, MA, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully individual antibodies against two targets selected by Biogen Idec.